Apixaban (Eliquis®) for NVAF

Assessment Status NCPE Assessment Process Complete
Drug Apixaban
Brand Eliquis®
Indication For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Assessment Process
Rapid review commissioned 07/12/2012
Rapid review completed 21/12/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 05/04/2013
NCPE assessment completed 31/05/2013
NCPE assessment outcome Reimbursement Recommended